ILUMYA DOSING & ADMINISTRATION

ENHANCE COMPLIANCE AND SEE YOUR PATIENTS' PROGRESS AT EVERY VISIT1

THE ONLY SINGLE-INJECTION IL-23 INHIBITOR WITH QUARTERLY DOSING2-4

1 DOSE = ONE 100 mg INJECTION

  • The 100 mg dose of ILUMYA™ is recommended for all patients, regardless of weight.2

TREATMENT OPTIONS FOR
MODERATE-TO-SEVERE PLAQUE PSORIASIS*

ILUMYA_1_YRCreated with Sketch.2INJECTIONS2ILUMYA(tildrakizumab)Following 2 starter doses at Weeks 0 and 4IL-23 INHIBITORONE 100 mg injection per Q12W maintenance dose
ILUMYA_1_YRCreated with Sketch.IL-23 INHIBITORILUMYA(tildrakizumab)6INJECTIONS2Following 2 starter doses at Weeks 0 and 4ONE 100 mg injection per Q12W maintenance dose
ILUMYA_1_YRCreated with Sketch.ILUMYA(tildrakizumab)10INJECTIONS2Following 2 starter doses at Weeks 0 and 4ONE 100 mg injection per Q12W maintenance doseIL-23 INHIBITOR

This graphic is not intended to compare the efficacy or safety of the treatments for moderate-to-severe plaque psoriasis shown here. Additional considerations, aside from the dosing profile, should be taken into account before making a treatment decision. For complete product information, refer to each product’s Prescribing Information.

*Indications and dosage information accessed May 2019. For complete product information, including current indications and dosing, refer to each product’s Prescribing Information.
Reflects adult dosing. One 45 mg or 90 mg injection per dose, based on weight (≤100 kg or >100 kg, respectively).
Dosing based on the recommended 300 mg dose. Some patients may receive a 150 mg dose.
§Reflects adult dosing. Alternative starting doses include 25 mg or 50 mg weekly.

Indicated trademarks are registered trademarks of their respective owners.
Skyrizi™ is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Tremfya® is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Stelara® is indicated for the treatment of patients 12 years or older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

Otezla® is indicated for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

Cosentyx® is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

Taltz® is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Enbrel® is indicated for the treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Humira® is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. Humira® should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician.

ICONCreated with Sketch.

HEALTHCARE PROFESSIONAL ADMINISTRATION

ILUMYA™ should only be administered by a healthcare professional, so you can ensure compliance and monitor your patient’s progress with every dose.2

appointment-2

ROOM TEMPERATURE STABILITY CAN ALLOW FOR STORAGE FLEXIBILITY

ILUMYA™ should be refrigerated. 30 minutes before injecting, let ILUMYA™ sit at room temperature. Once stored at room temperature, do not place back in the refrigerator. However, 30-day room temperature stability means ILUMYA™ can be administered later if your patient misses their appointment.2

ILUMYA™ IN ACTION

See how ILUMYA™ precisely targets the inflammatory pathway2

Watch MOA Video

RESPONSE THAT LASTS

See results through Week 14811

Explore Efficacy

INDICATION AND IMPORTANT SAFETY INFORMATION

ILUMYA™ (tildrakizumab-asmn) is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

CONTRAINDICATIONS

ILUMYA™ is contraindicated in patients with a previous serious hypersensitivity reaction to tildrakizumab or to any of the excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity

Cases of angioedema and urticaria occurred in ILUMYA™-treated subjects in clinical trials. If a serious allergic reaction occurs, discontinue ILUMYA™ immediately and initiate appropriate therapy.

Infections

ILUMYA™ may increase the risk of infection. Treatment with ILUMYA™ should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.

Consider the risks and benefits of treatment prior to prescribing ILUMYA™ in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving ILUMYA™ to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and consider discontinuation of ILUMYA™ until the infection resolves.

Pretreatment Evaluation for Tuberculosis

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with ILUMYA™. Do not administer ILUMYA™ to patients with active TB infection. Initiate treatment of latent TB prior to administering ILUMYA™. Consider anti-TB therapy prior to initiation of ILUMYA™ in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Patients receiving ILUMYA™ should be monitored closely for signs and symptoms of active TB during and after treatment.

Immunizations

Prior to initiating therapy with ILUMYA™, consider completion of all age-appropriate immunizations according to current immunization guidelines. Patients treated with ILUMYA™ should not receive live vaccines.

Adverse Reactions

The most common (≥1%) adverse reactions associated with ILUMYA™ treatment that were more frequent than in the placebo group are upper respiratory infections, injection-site reactions, and diarrhea.

Please see full Prescribing Information.

 

References: 1. Belinchón I, Rivera R, Blanch C, Comellas M, Lizán L. Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature. Patient Prefer Adherence. 2016;10:2357–2367. 2. ILUMYA™ [package insert]. Princeton, NJ: Sun Pharmaceuticals, Inc. 3. Skyrizi™ (risankizumab-rzaa) [package insert]. North Chicago, IL: AbbVie Inc. 4. Tremfya® (guselkumab) [prescribing information]. Horsham, PA: Janssen Biotech, Inc. 5. Stelara®(ustekinumab) [prescribing information]. Horsham, PA: Janssen Biotech, Inc. 6. Otezla® (apremilast) [package insert]. Summit, NJ: Celgene Corporation. 7. Cosentyx® (secukinumab) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation. 8. Taltz® (ixekizumab) [prescribing information]. Indianapolis, IN: Eli Lilly and Company. 9. Enbrel® (etanercept) [prescribing information]. Thousand Oaks, CA: Immunex Corporation. 10. Humira® (adalimumab) [prescribing information]. North Chicago, IL: AbbVie Inc. 11. Thaçi D, Iversen L, Pau-Charles I, et al. Long-term efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who were responders at week 28: pooled analysis through 3 years (148 weeks) from reSURFACE 1 and reSURFACE 2 phase 3 trials. Paper presented at: 27th Congress of the European Academy of Dermatology and Venereology (EADV); September 12-16, 2018; Paris, France.